



Suppl Fig 3: Comparison of the risk factors results (hazard ratios [HR] and confidence intervals [CI]) from the confounder-adjusted individual patient data meta-analysis between the atezolizumab (Atezo) and standard of care (SOC) arms. The color refers to the significance level (FDR adjusted p-values). One separate plot for each irAE type: A) Rash, B) Hepatitis, C) Pneumonitis.


A) Rash



B) Hepatitis




C) Pneumonitis




Suppl Fig 3: Comparison of the risk factors results (hazard ratios [HR] and confidence intervals [CI]) from the confounder-adjusted individual patient data meta-analysis between the atezolizumab (Atezo) and standard of care (SOC) arms. The color refers to the significance level (FDR adjusted p-values). One separate plot for each irAE type: A) Rash, B) Hepatitis, C) Pneumonitis, D) Hypothyroidism, E) Hyperthyroidism.

D) Hypothyroidism



E) Hyperthyroidism



- Atezo: FDR < 10% & SOC: FDR < 10%
- Atezo: FDR < 10% & SOC: FDR > 10%
- Atezo: FDR > 10% & SOC: FDR < 10%
- Atezo: FDR > 10% & SOC: FDR > 10%